PUBLISHER: TechNavio | PRODUCT CODE: 1910999
PUBLISHER: TechNavio | PRODUCT CODE: 1910999
The global non-insulin diabetes therapeutics market is forecasted to grow by USD 45361.6 mn during 2025-2030, accelerating at a CAGR of 11.5% during the forecast period. The report on the global non-insulin diabetes therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing number of people with type 2 diabetes, growing prevalence of diabetes among people aged 6-19 and 35-50, recent product approvals.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2026 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 10.9% |
| CAGR | 11.5% |
| Incremental Value | $45361.6 mn |
Technavio's global non-insulin diabetes therapeutics market is segmented as below:
By Type
By Distribution Channel
By Route Of Administration
Geography
This study identifies the innovations in therapies as one of the prime reasons driving the global non-insulin diabetes therapeutics market growth during the next few years. Also, strategic alliances between companies and increasing demand for combination drugs will lead to sizable demand in the market.
The report on the global non-insulin diabetes therapeutics market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global non-insulin diabetes therapeutics market vendors that include Abbott Laboratories, AstraZeneca Plc, Better Therapeutics Inc., Biocon Ltd., Boehringer Ingelheim GmbH, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services, Luye Pharma Group Ltd., Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Ltd.. Also, the global non-insulin diabetes therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.